Swiss/British drugmaker AstraZeneca has closed a new licensing agreement with Argentine firm GP Pharm, Pharmabiz can exclusively reveal.
Swiss/British drugmaker AstraZeneca has closed a new licensing agreement with Argentine firm GP Pharm, Pharmabiz can exclusively reveal.
The licensing and royalties agreement will see GP Pharm commercialise the injectable drugs Yectafer, Nubaína, Intrafer, Fentanilo and Remicit, which AZ produces at its plant in the west of Buenos Aires province.
GP Pharm general manager Eduardo Caules told Pharmabiz the objective was to complement the firm’s portfolio with specialised drugs for cancer and special therapies.
